Predictive Value of Plasma P-tau217 and *APOE* Genotype for Preclinical Cognitive Decline in Alzheimer's Disease

Yuexuan Xu, PhD[1,2], Tamil Iniyan Gunasekaran, PhD[1,2], Yian Gu, PhD[1-3], Dolly Reyes-Dumeyer, BS[1,2], Angel Piriz, MD[1], Danurys Sanchez, MS[1], Diones Rivera Mejia, MD[5,6], Martin Medrano, MD[7], Rafael A. Lantigua, MD[1,8], Lawrence Honig, MD, PhD[1-3], Rachael Wilson, PhD[10-11], Ramiro Eduardo Rea Reyes, PhD[10-11], Jennifer J Manly, PhD[1-3], Adam M. Brickman, PhD[1-3], Corinne D. Engelman, PhD[12], Sterling Johnson, PhD[10-11], Sanjay Asthana[10-11], MD, David A. Bennett, MD[13-14], Melissa Petersen[15-16], Sid O'Bryant, PhD[15-16], [#]Badri N. Vardarajan, PhD[1,2], and [#]Richard Mayeux, MD[1-3**]

1. Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA
2. G.H. Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA
3. Department of Neurology, Vagelos College of Physicians and Surgeons, Columbia University, and the New York Presbyterian Hospital, New York, NY, USA
4. Clínica Gregorio Hernandez, Puerto Plata, Dominican Republic
5. CEDIMAT, Santo Domingo, Dominican Republic
6. Universidad Pedro Henríquez Urena, Santo Domingo, Dominican Republic
7. Pontificia Universidad Católica Madre y Maestra (PUCMM), Santiago, Dominican Republic
8. Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, and the New York Presbyterian Hospital, New York, NY, USA
9. Clínica Corominas, Santiago, Dominican Republic
10. Department of Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA
11. Wisconsin Alzheimer's Institute, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA
12. Department of Population Health Sciences, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA
13. Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA.
14. Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
15. Institute for Translational Research, University of North Texas Health Science Center, Fort Worth, Texas, USA
16. Department of Family Medicine, University of North Texas Health Science Center, Fort Worth, Texas, USA

[#] Contributed equally to the manuscript.

Correspondence:

Richard Mayeux, MD
Neurological Institute
Columbia University
710 West 168th Street
New York, NY 10032
Telephone: (212)305-2391
Fax: (212)305-0241
E-mail: rpm2@cumc.columbia.edu

ABSTRACT

Background: *APOE*-ε4 is the strongest genetic risk factor for Alzheimer's disease (AD), and plasma phosphorylated tau217 (P-tau217) is a highly sensitive and specific biomarker for AD pathology. Their combined utility to predict cognitive decline before onset of AD has not been systematically evaluated.

Methods: Using longitudinal data from multiple cohorts, we evaluated plasma P-tau217 as a predictor of when cognitive impairment occurs in AD. P-tau217 concentrations were analyzed as continuous and binary variables using cohort-specific biomarker positivity thresholds. Association of plasma P-tau217 with prevalent and incident cognitive impairment were assessed using logistic regression and Cox models, stratified by *APOE* genotype. Adjusted survival curves and restricted mean survival time characterized when the onset of cognitive impairment occurred. Cohort-specific estimates were pooled using random-effects meta-analyses, and analyzed by discrimination performance with AUC, incremental R^2, and Harrell's C-index.

Results: Elevated P-tau217 levels were significantly associated with the onset of cognitive impairment. Among *APOE*-ε4 allele carriers, increased P-tau217 levels anticipated subsequent cognitive impairment. While P-tau217 levels reached clinically significant levels up to four years before onset of cognitive impairment independent of *APOE*, the symptom-free interval was briefest for *APOE*-ε4 carriers with elevated P-tau217.

Conclusions: Plasma P-tau217 levels and the presence *APOE* genotype can be used to estimate the interval before the onset of overt cognitive impairment and the diagnosis of AD. The findings here support the use of commercially available *APOE* genotyping and plasma P-tau217 to determine optimal timing for therapeutic intervention, particularly during the preclinical phase of the disease.

INTRODUCTION

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by a long preclinical phase, during which amyloid-beta (Aβ) plaques, tau neurofibrillary tangles, and other pathologies accumulate in the brain before the onset of overt cognitive symptoms.

Plasma-measured tau phosphorylated at threonine 217 (P-tau217) has emerged as a biomarker reflecting early AD-related amyloid and tau pathology[1], and strongly correlated with amyloid positron emission tomography uptake[2]. Elevated P-tau217 levels can precede clinical symptoms occurring in parallel with amyloid pathology[3,4]. Revised Alzheimer's Association criteria[5] have suggested including P-tau217 positivity to define preclinical AD without clinical symptoms.

The apolipoprotein E (*APOE*) ε4 allele is the most common genetic risk factor for AD. Individuals with one or two ε4 alleles develop pathology and symptoms earlier in life than non-carriers[6,7]. Individuals with *APOE* ε4 alleles progress to clinical disease within a given timeframe[8]. Plasma P-tau217 reflects early pathological changes, and *APOE* ε4 allele carriers are most likely to develop cognitive decline and AD. Therefore, evaluating P-tau217 in the context of *APOE* genotype may offer a powerful approach in determining when to initiate therapy and for refining risk prediction.

We analyzed longitudinal data from seven independent cohorts of diverse ethnic backgrounds to assess whether plasma P-tau217 and *APOE* genotyping can serve as an antecedent biomarker of cognitive impairment in AD. Analyses were conducted

separately for *APOE*-ε4 allele carriers and non-carriers. We also examined the time to cognitive impairment over the follow-up period.

METHODS

Participants

Longitudinal clinical data, *APOE* genotype, plasma P-tau217, and AD-related clinical outcomes, were included from the Wisconsin Registry for Alzheimer's Prevention (WRAP), the Wisconsin Alzheimer's Disease Research Center (Wisconsin-ADRC), the Alzheimer's Disease Neuroimaging Initiative (ADNI), the Estudio Familiar de Influencia Genética en Alzheimer (EFIGA), the Washington Heights, Hamilton Heights, Inwood Columbia Aging Project (WHICAP), the Religious Orders Study/Rush Memory and Aging Project (ROSMAP), and the Health & Aging Brain Study – Health Disparities (HABS-HD) [9–15]. The study design for each cohort has been summarized in the Supplementary Materials[9–16]. We combined WRAP and the Wisconsin-ADRC into a single Wisconsin cohort to increase sample size and include patients with AD. The Columbia University Medical Center Institutional Review Board approved the study. Data from each cohort were accessed with approval from the respective principal investigators and their data access committees. All analyses were conducted in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines.

APOE Genotyping and Plasma P-tau217 Measurement

Genotypes were generated using high-throughput platforms across cohorts, with quality control procedures described previously[17–19]. For analysis, participants were grouped as

ε4 carriers (ε3/ε4, ε4/ε4) and non-carriers (ε2/ε3, ε3/ε3). Individuals with *APOE* ε2/ε2 and ε2/ε4 genotypes were excluded due to rarity and potentially opposing or protective effects of the ε2 allele.

The acquisition and processing of plasma P-tau217 for each cohort was described previously (Supplementary Materials)[20–25]. P-tau217 values were $\log_{10}$-transformed to reduce skewness and then z-standardized within each cohort based on the cohort-specific mean and standard deviation to harmonize measurement scales and account for platform or batch effects. For analyses involving P-tau217 positivity, we applied a three-range approach and defined two cohort-specific thresholds *a priori*: one that maximized sensitivity for identifying amyloid-positive AD and another that maximized specificity to reduce false positives (Supplementary Table 1)[2]. EFIGA, ROSMAP, and HABS-HD included multiple ancestries and did not generate cohort-specific thresholds. We used the WHICAP multi-ethnic threshold as a proxy. In the sensitivity analyses, we repeated the analyses in these three cohorts using the threshold defined by WRAP.

Clinical Endpoints Assessment

All individuals were clinically diagnosed during study visits in each cohort[9,16,26,27], without use of the plasma biomarkers. Cognitively normal individuals did not meet AD-related diagnostic criteria or mild cognitive impairment (MCI, Supplementary materials). Cohorts varied substantially in age at recruitment and number of individuals with clinically diagnosed AD and MCI (Table 1). To increase comparability across the AD clinical spectrum and reflect the earliest changes of AD, we combined AD and MCI as a cognitively impaired group and cognitively unimpaired individuals as normal.

Statistical Analysis

Plasma biomarker data varied in availability and longitudinal follow-up across cohorts. WHICAP and EFIGA had only cross-sectional P-tau217 data, ADNI and ROSMAP had limited follow-up, while WRAP and HABS-HD had more extensive follow-up. However, all cohorts included longitudinal clinical assessment data. To maximize comparability, we defined baseline as the first clinical assessment for biomarkers. We reported sample characteristics and summarized P-tau217 levels by cognitive status, age group (<=70 and >70), and *APOE*-ε4 status. Cohort-specific associations between baseline P-tau217 and cognitive impairment were evaluated using logistic regression, stratified by *APOE*-ε4 status, and we tested the *APOE*-ε4 by P-tau217 interaction. We then evaluated the association between *APOE*-ε4 and plasma P-tau217 in the full dataset, and repeated the analyses in cognitively unimpaired and separately, P-tau217-negative individuals. Finally, we tested the association between *APOE*-ε4 and P-tau217 positivity in each cohort. Models were adjusted for age, sex, education (in years), ethnic group, and *APOE* genotype (except when *APOE*-ε4 was the predictor).

For longitudinal analyses, Cox proportional hazards models adjusted for age, sex, education (in years), *APOE* genotype, and ethnic group were used to assess whether baseline P-tau217 levels or biomarker positivity anticipated incident cognitive impairment (MCI or AD) among individuals cognitively unimpaired. In cohorts with small or rare *APOE* genotypes (e.g., EFIGA), association models did not adjust for *APOE* genotype. Incident events were dated from baseline to cognitive impairment; all others were censored at last evaluation. The proportional hazards assumption was tested using Schoenfeld residuals[28]. We also repeated the analyses stratified by *APOE*-ε4 status and tested

APOE-ε4 by P-tau217 interaction. Random-effects meta-analyses combined results across cohorts to evaluate (1) P-tau217 association with cognitive impairment at baseline, (2) *APOE* effects on P-tau217 at baseline, and (3) the hazard ratio (HR) of baseline P-tau217 for incident cognitive impairment, overall and within subgroups stratified by the *APOE*-ε4 allele.

To investigate the temporal trajectory and prognostic utility of P-tau217, we conducted three post hoc analyses by pooling data across all cohorts to increase statistical power. First, we estimated covariate-adjusted survival curves at pre-defined and clinically relevant P-tau217 levels (e.g., mean and +1 standard deviation [SD] based on each cohort's distribution) and stratified by risk categories to identify the earliest divergence in survival probabilities[29–35]. To further quantify this divergence, we also compared the time of 75% cognitive-impairment–free survival to account for younger individuals who did not reach median survival. The proportional hazards assumption was violated in the combined sample for the P-tau217 positivity models due to heterogeneity across datasets; thus we applied a pseudo-value approach[24]. This method estimates survival at prespecified time points, fits generalized estimating equations to adjust for covariates, and averages predictions across groups to yield confounder-adjusted trajectories, with 1,000 bootstrap resamples for confidence intervals. When P-tau217 was modeled as continuous, a pseudo-value model was not available, therefore we stratified on the covariates that failed the proportional hazards test before plotting the survival curves.

Second, we estimated model–based restricted mean survival time (RMST) for remaining cognitively unimpaired over the full follow-up (Supplementary materials). For the first and second post-hoc analyses, we applied the Benjamini–Yekutieli FDR (BY-FDR) procedure,

which accommodates dependence among tests. For comparability across strata, survival and RMST estimates were truncated at the latest shared event time (e.g., 14 years for *APOE*-ε4 carriers).

Third, we assessed the prognostic performance of P-tau217 and *APOE*-ε4 for cognitive impairment using the area under the ROC curve (AUC) and the incremental change in R^2 from baseline and Harrell's concordance index (C-index) longitudinally. In the combined sample, stratification was applied for covariates violating the proportional hazards assumption. As sensitivity analyses, we repeated the survival, RMST, and discrimination analyses within each cohort.

All post hoc analyses included all cohorts and stratified by *APOE*-ε4 status (if applicable). Analyses were performed in R (v4.2.2), with package details provided in the Supplementary Materials.

RESULTS

Plasma P-tau217 and Cognitive Impairment at Baseline

Descriptive statistics for the entire dataset at baseline are presented in Table 1, and those for the subset in the longitudinal analysis are presented in Supplementary Table 2. Overall, P-tau217 concentrations were higher in cognitively impaired individuals compared to individuals without cognitive impairment (Supplementary Figure 1). Differences were more pronounced among *APOE*-ε4 carriers, including younger participants, with greater elevations in both magnitude and statistical significance across most datasets.

Statistically significant associations between P-tau217 and baseline cognitive impairment were observed in the Wisconsin, ADNI, EFIGA, ROSMAP, and HABS-HD datasets (Figure 1A). Subgroup meta-analyses across cohorts demonstrated significant associations between P-tau217 and cognitive impairment in both *APOE*-ε4 carriers and non-carriers, with the stronger effects observed among *APOE*-ε4 carriers. A significant P-tau217 by *APOE*-ε4 interaction was observed in the combined sample, in Wisconsin and ADNI, and was marginal in EFIGA (Figure 1B-1C).

Plasma P-tau217 and APOE-ε4

Study-specific analyses showed that *APOE*-ε4 was significantly associated with P-tau217 levels in all cohorts and separately in cognitively unimpaired individuals within each cohort (Figure 2A). *APOE*-ε4 was also associated with P-tau217 levels among biomarker negative individuals, whether the cutoff was defined using sensitivity- or specificity- based threshold. Likewise, *APOE*-ε4 was associated with P-tau217 positivity across both sensitivity- and specificity-based cutoffs (Figure 2B). Notably, the association demonstrated essentially no heterogeneity across cohorts among cognitively normal and P-tau217–negative individuals when the sensitivity-based cutoff was applied.

Baseline P-tau217 and Longitudinal Risk of Cognitive Impairment

Higher baseline levels of P-tau217 were significantly associated with increased risk of incident cognitive impairment in the Wisconsin, ADNI, WHICAP, ROSMAP, and HABS-HD datasets (Figure 3A). This effect was stronger among *APOE*-ε4 carriers, for whom P-tau217 significantly predicted incident cognitive impairment in the Wisconsin, ADNI,

WHICAP, ROSMAP, and HABS-HD datasets, whereas among non-carriers, significant associations were limited to Wisconsin, EFIGA, ROSMAP, and HABS-HD cohorts.

Using the sensitivity-based cutoff as a binary variable, P-tau217 biomarker positivity was associated with incident cognitive impairment in all cohorts except WHICAP, with the strongest effects observed among *APOE*-ε4 carriers (Figure 3B). When the specificity-based cutoff was applied, P-tau217 positivity was associated with incident cognitive impairment in all cohorts, again with the strongest overall effect observed among *APOE*-ε4 carriers (Figure 3C).

A statistically significant P-tau217 × *APOE*-ε4 interaction was observed in the combined sample, when P-tau217 was modeled as a continuous ($p < 0.001$) or a binary variable defined using cutoffs that maximize sensitivity ($p = 0.005$) or specificity ($p = 0.011$). In individual cohorts, statistically significant interactions were observed only in cohorts enriched with non-Hispanic White participants (e.g., Wisconsin and ADNI, Supplementary Table 3).

Temporal Dynamics of P-tau217 in Predicting the Onset of Cognitive Impairment

Based on the pooled data using continuous P-tau217, adjusted survival curves starting at baseline showed minimal differences in cognitive impairment between individuals with P-tau217 higher than one SD versus the mean before year 3 (BY-FDR–adjusted, Figure 3A). However, divergence in cognitive-impairment–free survival emerged after year 3 in the full group and at year 4 among *APOE*-ε4 carriers, but not among non-carriers, after which individuals with higher P-tau217 levels experienced greater cognitive decline. Similar patterns were observed when P-tau217 positivity was defined using the

sensitivity-based cutoff (Figure 3B). When the specificity-based cutoff (Figure 3C) was applied, divergence occurred earlier—approximately 1–2 years after baseline—in the full sample regardless of *APOE* genotype.

Individuals with continuous P-tau217 levels, 1 SD above the mean, reached the end of the 75% cognitive-impairment–free survival period 1.4 years earlier than those at the mean. Among *APOE*-ε4 carriers, elevated P-tau217 was associated with a 1.8-year earlier decline, and among non-carriers, with a 0.8-year earlier decline. These differences summarize the separation between model-adjusted survival curves but do not correspond to directly estimated model parameters. With the sensitivity-based cut-off, baseline P-tau217–positive individuals reached the end of the 75% cognitive-impairment–free survival period about 1.6 years (95% CI, 0.1-3.1, $p = 0.04$) earlier than P-tau217-negative individuals; the corresponding differences were 2.6 years (95% CI, 1.3-3.8, $p < 0.001$) among *APOE*-ε4 carriers and 1.1 years (95% CI, -1.2-3.4, $p = 0.365$) among non-carriers. Using the specificity-based cutoff, P-tau217-positive individuals reached 75% cognitive-impairment–free survival period approximately 2.8 years earlier overall (95% CI, 1.5-4.1, $p < 0.001$), with earlier declines of 2.8 years (95% CI, 1.8-3.7, $p < 0.001$) among *APOE*-ε4 carriers and 2.4 years (95% CI, 0.4-4.4, $p = 0.016$) among non-carriers. Similar findings were observed in the RMST analyses (Supplementary Figure 2), and results were consistent across cohorts (Survival curve: Supplementary Figures 3–5; RMST: Supplementary Figures 6-8).

Discrimination analyses showed strong predictive performance at baseline for both P-tau217 (AUC-continuous = 0.795; AUC-positivity (sensitivity-cutoff) = 0.784; AUC-positivity (specificity-cutoff) = 0.797) and *APOE*-ε4 (AUC = 0.774), with the highest AUC

observed for P-tau217 among *APOE*-ε4 carriers (AUC-continuous = 0.835; AUC-positivity (sensitivity-cutoff) = 0.816; AUC-positivity (specificity-cutoff) = 0.833). Similar patterns were observed for incremental R^2 and longitudinal C-index estimates (Figure 4), consistent across most cohorts (Supplementary Figures 9-14). Results for the temporal dynamics of P-tau217 and its prognostic ability in predicting the onset of cognitive impairment were consistent in the combined sample when a uniform cutoff derived from the Wisconsin cohort was applied consistently across all cohorts (Supplementary Figure 15-16).

DISCUSSION

In this study of over 8,000 individuals from seven cohorts with diverse ethnic backgrounds, plasma P-tau217 and the *APOE* genotype anticipated when the onset of cognitive impairment would occur among individuals who subsequently developed AD. Elevated P-tau217 was associated with increased risk of cognitive impairment at baseline and subsequently at follow-up. Plasma P-tau217 was associated with earlier onset of cognitive impairment across all cohorts. *APOE*-ε4 carriers with elevated P-tau217 showed a higher risk and earlier progression of cognitive impairment. A lag period of up to 4 years was observed before divergence, indicating an initial period when cognitive performance overlapped between individuals with high or low baseline P-tau217. Divergence occurred earlier in *APOE*-ε4 carriers despite the smaller sample size and limited power, suggesting that this pattern reflects a true biological effect. These findings likely indicate that *APOE-ε4* carriers with elevated P-tau217 levels reflect true AD pathology, whereas non-carriers

may experience cognitive impairment due to other disorders[36–38]. This could explain why P-tau217 predicts earlier cognitive impairment in *APOE*-ε4 carriers than non-carriers.

The prognostic value of plasma P-tau217 on cognitive impairment varied slightly by ethnic group, appearing stronger in non-Hispanic white cohorts than in more ethnically diverse populations, consistent with previous findings[39]. Although *APOE*-ε4 has a weaker effect on clinical AD risk in individuals of Hispanic and African ancestry[40], the association with P-tau217 was consistent, supporting prior evidence that P-tau217 reflects amyloid and tau pathology in diverse populations[41,42]. Notably, the association between *APOE*-ε4 and P-tau217 showed very little heterogeneity among cognitively unimpaired or truly P-tau217–negative individuals, across different ethnic backgrounds, suggesting that *APOE*-ε4 influences P-tau changes across populations at the earliest disease stage.

Elevated P-tau217 levels preceded clinical symptoms by up to four years. Minimal differences in survival estimates were found between individuals with high or low P-tau217 by 4 years after baseline, but differences in survival increased with progressive divergence after 4 years. This lag period was consistent across cohorts in the pooled analyses, across cohorts with different ethnic compositions and biomarker positivity thresholds, regardless of whether P-tau217 was modeled as a binary or continuous variable. This pattern aligns with biomarker-defined AD frameworks, in which pathological changes emerge well before the onset of clinical symptoms, and underscores a critical window for therapeutic intervention or trial enrollment[43].

While the pooled analyses suggested that the lag period was similar between *APOE*-ε4 carriers and non-carriers - particularly when baseline P-tau217 positivity was defined using the specificity cut-off- this pattern was not consistent across cohorts. In cohort

enriched for non-Hispanic white individuals, the duration of overlap in cognitive-impairment–free survival between individuals with high or low baseline P-tau217 was less among *APOE*-ε4 carriers than among non-carriers, whereas these differences were not evident in Hispanic and African cohorts. The cohort-specific inconsistency in lag period by *APOE*-ε4 likely reflects known ethnic differences in the effect of *APOE*-ε4 on AD[40].

We measured P-tau217 at a single time point in most cohorts, missing any longitudinal within-person changes. Thresholds for P-tau217 positivity may have varied across cohorts due to assay and population differences; although continuous measures were harmonized, variation in binary classification may have affected generalizability of cut-off–based risk estimates. Cohort-specific thresholds were not available for all studies, requiring the use of the WHICAP threshold as a proxy, representing an additional limitation. Adjusted survival curves and RMST analyses suggested that P-tau217-related hazards may vary over time. However, limited sample sizes and events within individual cohorts, and substantial heterogeneity in baseline hazards and follow-up structures, made precise estimation of time-dependent hazard ratios difficult, even in the combined sample.

Assays for plasma P-tau217 and *APOE* genotyping are widely commercially available. As demonstrated, used together they represent robust early predictors of cognitive impairment, particularly among *APOE*-ε4 carriers. This “not if, but when” observation provides the ability to identify at-risk individuals with AD, years before symptom onset defining a window for therapeutic intervention. Although prognostic strength varied by ethnicity for clinical diagnosis, its relationship with underlying AD biology appeared

consistent across ethnic groups, supporting the broad clinical utility of P-tau217 for early detection and therapy in AD.

Reference

1. Therriault J, Ashton NJ, Pola I, et al. Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer's pathology. eBioMedicine [Internet] 2024 [cited 2025 Aug 9];102. Available from: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(24)00081-1/fulltext

2. Ashton NJ, Brum WS, Di Molfetta G, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol 2024;81(3):255–63.

3. Yakoub Y, Gonzalez-Ortiz F, Ashton NJ, et al. Plasma p-tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10-year window. Alzheimer's & Dementia 2025;21(2):e14537.

4. De Meyer S, Schaeverbeke JM, Luckett ES, et al. Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET. Brain Commun 2024;6(4):fcae162.

5. Jack Jr. CR, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & Dementia 2024;20(8):5143–69.

6. Liu C-C, Zhao N, Fu Y, et al. ApoE4 accelerates early seeding of amyloid pathology. Neuron 2017;96(5):1024-1032.e3.

7. Lim YY, Mormino EC, For the Alzheimer's Disease Neuroimaging Initiative. APOE genotype and early β-amyloid accumulation in older adults without dementia. Neurology 2017;89(10):1028–34.

8. Polsinelli AJ, Lane KA, Manchella MK, Logan PE, Gao S, Apostolova LG. APOE ε4 is associated with earlier symptom onset in LOAD but later symptom onset in EOAD. Alzheimer's & Dementia 2023;19(5):2212–7.

9. Johnson SC, Koscik RL, Jonaitis EM, et al. The Wisconsin Registry for Alzheimer's Prevention: A review of findings and current directions. Alzheimers Dement (Amst) 2018;10:130–42.

10. Ma Y, Mora Pinzon MC, Buckingham WR, et al. Comparison of sample characteristics of Wisconsin Alzheimer's Disease Research Center participants with the Wisconsin state population—An evaluation of the recruitment effort. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2025;11(1):e70036.

11. Rivera Mindt M, Arentoft A, Calcetas AT, et al. The Alzheimer's Disease Neuroimaging Initiative-4 (ADNI-4) Engagement Core: A culturally informed,

community-engaged research (CI-CER) model to advance brain health equity. Alzheimer's & Dementia 2024;20(12):8279–93.

12. Gu Y, Honig LS, Kang MS, et al. Risk of Alzheimer's disease is associated with longitudinal changes in plasma biomarkers in the multi-ethnic Washington Heights–Hamilton Heights–Inwood Columbia Aging Project (WHICAP) cohort. Alzheimer's & Dementia 2024;20(3):1988–99.

13. Vardarajan BN, Faber KM, Bird TD, et al. Age-Specific Incidence Rates for Dementia and Alzheimer Disease in NIA-LOAD/NCRAD and EFIGA Families. JAMA Neurol 2014;71(3):315–23.

14. Bennett DA, Buchman AS, Boyle PA, Barnes LL, Wilson RS, Schneider JA. Religious Orders Study and Rush Memory and Aging Project. Journal of Alzheimer's Disease 2018;64(s1):S161–89.

15. Petersen ME, Zhou Z, Hall JR, et al. Health and Aging Brain Study–Health Disparities (HABS-HD) methods and partner characteristics. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2025;11(3):e70140.

16. Xu Y, Qiao M, Gunasekaran TI, et al. Evaluating polygenic risk score prediction performance for Alzheimer's disease in a population-based Hispanic cohort using single- and multi-ancestry models. The Lancet Regional Health – Americas [Internet] 2025 [cited 2025 Aug 9];49. Available from: https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(25)00208-X/fulltext

17. Pérez-González AP, García-Kroepfly AL, Pérez-Fuentes KA, et al. The ROSMAP project: aging and neurodegenerative diseases through omic sciences. Front Neuroinform [Internet] 2024 [cited 2025 Dec 7];18. Available from: https://www.frontiersin.org/journals/neuroinformatics/articles/10.3389/fninf.2024.1443865/full

18. O'Bryant SE, Petersen M, Hall J, Johnson L. APOEε4 Genotype Is Related to Brain Amyloid Among Mexican Americans in the HABS-HD Study. Front Neurol 2022;13:834685.

19. Xu Y, Qiao M, Gunasekaran TI, et al. Polygenic scores of Core 1 Alzheimer's disease biomarkers predict early cognitive and pathological change. Alzheimers Dement 2025;21(11):e70937.

20. Du L, Langhough RE, Wilson RE, et al. Longitudinal plasma phosphorylated-tau217 and other related biomarkers in a non-demented Alzheimer's risk-enhanced sample. Alzheimer's & Dementia 2024;20(9):6183–204.

21. Brickman AM, Manly JJ, Honig LS, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. Alzheimer's & Dementia 2021;17(8):1353–64.

22. Eissman JM, Ma Y, Qiao M, et al. Biological Age and Age Acceleration Predict Alzheimer's Disease Plasma Biomarker Levels [Internet]. 2025 [cited 2025 Aug 9];2025.05.22.25328181. Available from: https://www.medrxiv.org/content/10.1101/2025.05.22.25328181v3

23. Shaw LM, Korecka M, Lee EB, et al. ADNI Biomarker Core: A review of progress since 2004 and future challenges. Alzheimer's & Dementia 2025;21(1):e14264.

24. Yu L, Boyle PA, Janelidze S, et al. Plasma p-tau181 and p-tau217 in discriminating PART, AD and other key neuropathologies in older adults. Acta Neuropathol 2023;146(1):1–11.

25. Yu L, Du L, Wang T, et al. Neuropathologic correlates of distinct plasma biomarker profiles in community-living older adults. Brain 2025;148(9):3340–9.

26. Aisen PS, Donohue MC, Raman R, Rafii MS, Petersen RC, Initiative for the ADN. The Alzheimer's Disease Neuroimaging Initiative Clinical Core. Alzheimer's & Dementia 2024;20(10):7361–8.

27. Karpouzian-Rogers T, Ho E, Novack M, et al. Baseline characterization of the ARMADA (Assessing Reliable Measurement in Alzheimer's Disease) study cohorts. Alzheimer's & Dementia 2023;19(5):1974–82.

28. Schoenfeld D. Chi-Squared Goodness-of-Fit Tests for the Proportional Hazards Regression Model. Biometrika 1980;67(1):145–53.

29. Coory M, Lamb KE, Sorich M. Risk-difference curves can be used to communicate time-dependent effects of adjuvant therapies for early stage cancer. Journal of Clinical Epidemiology 2014;67(9):966–72.

30. Andersen PK, Syriopoulou E, Parner ET. Causal inference in survival analysis using pseudo-observations. Statistics in Medicine 2017;36(17):2669–81.

31. Andersen PK, Pohar Perme M. Pseudo-observations in survival analysis. Stat Methods Med Res 2010;19(1):71–99.

32. Perperoglou A, Sauerbrei W, Abrahamowicz M, Schmid M. A review of spline function procedures in R. BMC Medical Research Methodology 2019;19(1):46.

33. Overgaard M, Parner ET, Pedersen J. Pseudo-observations under covariate-dependent censoring. Journal of Statistical Planning and Inference 2019;202:112–22.

34. Binder N, Gerds TA, Andersen PK. Pseudo-observations for competing risks with covariate dependent censoring. Lifetime Data Anal 2014;20(2):303–15.

35. Denz R, Klaaßen-Mielke R, Timmesfeld N. A comparison of different methods to adjust survival curves for confounders. Statistics in Medicine 2023;42(10):1461–79.

36. Shriram J, Malek-Ahmadi M, Irwin C, Sabbagh M. Impact of incidental synucleinopathy in mild cognitive impairment due to Alzheimer disease. J Neuropathol Exp Neurol 2024;83(4):230–7.

37. Gunasekaran TI, Sanchez D, Reyes-Dumeyer D, et al. Frequency of Microvascular Pathology and Hippocampal Atrophy on Magnetic Resonance Imaging in a Community Study of Alzheimer's Disease with Blood-Based Biomarkers. Annals of Neurology 2025;98(5):1027–43.

38. Sekiya H, Matsubara T, DeTure MA, Dickson DW. Neuropathology of Lewy body dementia: Lewy-related pathology, α-synuclein oligomers, and comorbid pathologies. Mol Neurodegeneration 2025;20(1):117.

39. Nayyar A, Li M, Sotelo V, et al. Influence of cognitive impairment and race on plasma p-Tau217 in two diverse cohorts. Alzheimer's & Dementia 2025;21(2):e14585.

40. Belloy ME, Andrews SJ, Le Guen Y, et al. APOE Genotype and Alzheimer Disease Risk Across Age, Sex, and Population Ancestry. JAMA Neurology 2023;80(12):1284–94.

41. Molina-Henry D, Langford O, Donohue MC, et al. Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4. J Prev Alzheimers Dis 2024;11(4):831–7.

42. Kjaergaard D, Nielsen TR, Stomrud E, et al. Influence of ethnicity on the diagnostic accuracy of plasma p-tau217 for the identification of Alzheimer's disease: A consecutive mixed memory clinic cohort study. Alzheimer's & Dementia 2025;21(6):e70315.

43. Jia J, Ning Y, Chen M, et al. Biomarker Changes during 20 Years Preceding Alzheimer's Disease. New England Journal of Medicine 2024;390(8):712–22.

Data availability statement:

The data analyzed in this study are subject to the following licenses/restrictions: datasets can be requested through formal research applications to the Washington Heights-Inwood Columbia Aging Project and the Genetic Studies of Alzheimer's Disease in Caribbean Hispanics (EFIGA). Requests to access these datasets should be directed to the Columbia University Alzheimer's Disease Research Center: https://www.neurology.columbia.edu/research/research-centers-and-programs/alzheimers-disease-research-center-adrc/investigators/investigator-resources.

Data may also be requested from the Wisconsin Registry for Alzheimer's Prevention and the Wisconsin Alzheimer's Disease Research Center via: https://wrap.wisc.edu/data-requests-2/, from the Alzheimer's Disease Neuroimaging Initiative (ADNI): https://adni.loni.usc.edu/data-samples/adni-data/, from the Health & Aging Brain Study (HABS-HD): https://apps.unthsc.edu/itr/our/, and from the Religious Orders Study and Memory and Aging Project (ROSMAP): https://www.radc.rush.edu/requests.htm.

Ethics statement:

The studies involving humans were approved by the Institutional Review Board of the Columbia University Medical Center. The studies were conducted in accordance with the local legislation and institutional requirements. Subjects from WRAP, Wisconsin-ADRC, WHICAP, EFIGA, ROSMAP, and HABS-HD have provided signed informed consent before participation.

Conflict of interest:

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author contributions:

YX, BV, and RM contributed to the study design. YX, TG, RM, BV, DR, LH, and YG prepared the data and performed the data analysis. YX, BV, and RM drafted the manuscript. All authors critically reviewed the manuscript and have approved the final version.

Funding:

This work was supported by the National Institute on Aging (NIA) and the National Institutes of Health (NIH). Data collection and research activities were funded through multiple grants, including support for the Genetic Studies of Alzheimer's Disease in Caribbean Hispanics (EFIGA: R01 AG067501), the Washington Heights-Inwood Columbia Aging Project (WHICAP: R01 AG072474, RF1 AG066107), and the National Center for Advancing Translational Sciences (NCATS) through Grant Number

UL1TR001873. Additional support was provided for the Wisconsin Registry for Alzheimer's Prevention (WRAP: R01 AG027161), the Genomic and Metabolomic Data Integration in a Longitudinal Cohort at Risk for Alzheimer's Disease (R01 AG054047, RF1 AG054047), and the Wisconsin Alzheimer's Disease Research Center (P30 AG062715). Data collection and sharing for the Alzheimer's Disease Neuroimaging Initiative (ADNI) were funded by the National Institute on Aging (National Institutes of Health Grant U19AG024904). The grantee organization is the Northern California Institute for Research and Education. ADNI has also received support from the National Institute of Biomedical Imaging and Bioengineering, the Canadian Institutes of Health Research, and private sector contributions through the Foundation for the National Institutes of Health (FNIH), including generous donations from the following organizations: AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. We are deeply grateful to all participants, researchers, and collaborators who contributed to this study. ROSMAP is supported by P30AG10161, P30AG72975, R01AG17917. R01 AG015819, R01 AG34374, U01 AG072572, and U01 AG046152.Research reported for HABS-HD was supported by the NIA/NIH under Award Numbers R01AG054073, R01AG058533, R01AG070862, P41EB015922 and U19AG078109.

Acknowledgements:

We acknowledge the participants from the Washington Heights-Inwood Columbia Aging Project (WHICAP), the Genetic Studies of Alzheimer's Disease in Caribbean Hispanics (EFIGA), the Wisconsin Registry for Alzheimer's Prevention (WRAP), the Wisconsin Alzheimer's Disease Research Center (Wisconsin ADRC), the Health & Aging Brain Study – Health Disparities (HABS-HD), the Religious Orders Study and Rush Memory and Aging Project (ROSMAP), and the Alzheimer's Disease Neuroimaging Initiative (ADNI) for their invaluable contributions and dedication. This study would not be possible without their continued participation. We also thank the researchers and study teams involved in WHICAP, EFIGA, WRAP, the Wisconsin ADRC, HABS-HD, ROSMAP, and ADNI for their longstanding efforts in data collection and subject follow-up over the years. The authors wish to acknowledge and thank the physicians in the Dominican Republic, Belisa Soriano, MD, Yahaira Franco, MD, Zoraida Dominguez Coronado, MD, Patricia Recio, MD for their help recruiting individuals in the EFIGA study. Author YX would also

like to thank Yuanyuan Qiao for her patience, support, and assistance with proofreading this study.

Table 1. Baseline characteristics of participants included in the analysis

Characteristic	ADNI N = 985[1]	EFIGA N = 1,426[1]	HABS-HD N = 2,479[1]	ROSMAP N = 1,035[1]	WHICAP N = 1,018[1]	Wisconsin N = 1,639[1]
Age at baseline (years)	74 (8)	72 (8)	66 (9)	79 (8)	76 (7)	63 (8)
Sex						
Women	479 (49%)	960 (67%)	1,546 (62%)	844 (82%)	700 (69%)	1,123 (69%)
Men	506 (51%)	466 (33%)	933 (38%)	191 (18%)	318 (31%)	516 (31%)
Education (years)	16 (3)	6 (5)	13 (4)	16 (4)	11 (5)	16 (2)
Initial P-tau217 (pg/mL)	0.32 (0.34)	0.46 (0.42)	0.43 (0.46)	0.69 (0.62)	0.45 (0.35)	0.38 (0.27)
Initial P-tau217 positivity (sensitivity-cutoff)						
Negative	484 (49%)	922 (65%)	1,698 (68%)	371 (36%)	628 (62%)	1,177 (72%)
Positive	501 (51%)	504 (35%)	781 (32%)	664 (64%)	390 (38%)	462 (28%)
Initial P-tau217 positivity (specificity-cutoff)						
Negative	669 (68%)	1,255 (88%)	2,230 (90%)	758 (73%)	908 (89%)	1,452 (89%)
Positive	316 (32%)	171 (12%)	249 (10%)	277 (27%)	110 (11%)	187 (11%)
Initial cognitive status[2]						
Prevalent cognitive impairment	464 (47%)	606 (42%)	627 (25%)	285 (28%)	205 (20%)	80 (4.9%)
Normal at baseline & No Follow-up	120 (12%)	491 (34%)	683 (28%)	18 (1.7%)	13 (1.3%)	421 (26%)
Normal at baseline & Has Follow-up	401 (41%)	329 (23%)	1,169 (47%)	732 (71%)	800 (79%)	1,138 (69%)
Ethnic Group[3]						
Black	109 (11%)	0 (0%)	529 (21%)	380 (37%)	260 (26%)	102 (6.2%)
Non-Hispanic White	816 (83%)	0 (0%)	956 (39%)	574 (55%)	256 (25%)	1,454 (89%)
Others and Hispanics	60 (6.1%)	1,426 (100%)	994 (40%)	81 (7.8%)	502 (49%)	83 (5.1%)
***APOE*[4]**						
2/3	80 (8.1%)	164 (12%)	258 (10%)	139 (13%)	146 (14%)	148 (9.0%)
3/3	472 (48%)	796 (56%)	1,563 (63%)	618 (60%)	625 (61%)	883 (54%)
3/4	343 (35%)	405 (28%)	595 (24%)	251 (24%)	228 (22%)	530 (32%)
4/4	90 (9.1%)	61 (4.3%)	63 (2.5%)	27 (2.6%)	19 (1.9%)	78 (4.8%)

[1] Mean (SD); n (%)

Table 1 presents summary statistics for the baseline characteristics of the biomarker analytic sample across cohorts. Biomarker availability and longitudinal follow-up varied by cohort; the baseline sample reflects the first available plasma

biomarker measurement for each participant. For cohorts with only cross-sectional biomarker data, this represents a single time point; for longitudinal cohorts, it corresponds to the first time a biomarker was collected.

[2] Baseline cognitive status was defined at the time when plasma biomarker data first became available for each participant. Cognitive impairment at follow-up reflects diagnoses made after this baseline assessment; any cognitive status assessments prior to biomarker availability were not considered.

[3] Ethnic group identity was collected in detail within each cohort; however, the distribution varied substantially across studies. For example, Wisconsin and ADNI were predominantly composed of non-Hispanic White participants, followed by Black individuals, with very few Hispanic or other ethnic groups. In contrast, EFIGA included only Hispanic participants, while WHICAP had a more balanced ethnic composition. To facilitate analysis and ensure adequate sample sizes within each category, we combined Hispanic and other ethnic groups into a single category. This grouping also helped stabilize regression models by reducing sparse categories and improving model convergence.

[4] *APOE* ε2/ε2 and ε2/ε4 genotypes were excluded due to their low frequency and the potentially protective effects of the ε2 allele, which may confound interpretation of *APOE*-ε4–related risk associations.

Figure 1. Cohort-specific associations between plasma P-tau217 and clinical cognitive impairment, with meta-analysis estimates in the full sample and stratified subgroups (A), and *APOE*-ε4 × P-tau217 interactions in the combined sample (B) and individual cohorts (C).

Figure 1 presents cohort-specific associations between harmonized plasma P-tau217 and clinical cognitive impairment, along with meta-analytic estimates in the full sample and stratified subgroups (A). We also evaluated *APOE*-ε4 × P-tau217 interactions in the combined sample, which included all cohorts (B), as well as within each individual cohort (C). Analyses were conducted at the time of first available biomarker measurement. For cohorts with only cross-sectional data, this corresponds to a single time point; for longitudinal cohorts, it reflects the earliest available measure. Plasma P-tau217 was harmonized using $\log_{10}$ transformation and z-standardization. Associations were tested using logistic regression models adjusted for age, sex, education, ethnic group, and *APOE* genotype; Within each full or stratified subgroup, random-effects meta-analyses were performed using cohort-specific ORs. Cognitive impairment was defined as a diagnosis of MCI or AD.


A
Study OR (95% CI) P (OR) N-Impaired N-Normal
Analysis = P-tau217(log-z)~Clinical AD
Wisconsin 2.44 [1.88; 3.15] 0.00 80 1559
ADNI 2.77 [2.30; 3.34] 0.00 464 521
EFIGA 1.49 [1.30; 1.71] 0.00 606 820
WHICAP 1.19 [0.99; 1.44] 0.06 205 813
ROSMAP 1.70 [1.43; 2.02] 0.00 285 750
HABS-HD 1.58 [1.42; 1.77] 0.00 627 1852
Random effects model 1.77 [1.42; 2.20]
Heterogeneity: I² = 90.5%
Analysis = P-tau217(log-z)~Clinical AD among ε3ε4/ε4ε4 carriers
Wisconsin 4.43 [2.70; 7.26] 0.00 39 569
ADNI 5.03 [3.56; 7.12] 0.00 250 183
EFIGA 1.71 [1.35; 2.15] 0.00 232 234
WHICAP 1.14 [0.81; 1.62] 0.46 49 198
ROSMAP 1.98 [1.41; 2.78] 0.00 91 187
HABS-HD 1.72 [1.40; 2.11] 0.00 202 456
Random effects model 2.25 [1.52; 3.34]
Heterogeneity: I² = 90.2%
Analysis = P-tau217(log-z)~Clinical AD among ε2ε3/ε3ε3 carriers
Wisconsin 1.62 [1.14; 2.32] 0.01 41 990
ADNI 1.98 [1.59; 2.48] 0.00 214 338
EFIGA 1.39 [1.17; 1.64] 0.00 374 586
WHICAP 1.21 [0.97; 1.51] 0.08 156 615
ROSMAP 1.59 [1.30; 1.95] 0.00 194 563
HABS-HD 1.52 [1.33; 1.73] 0.00 425 1396
Random effects model 1.52 [1.35; 1.72]
Heterogeneity: I² = 54.2%
0.3 0.5 1 2 10
B
Combined sample
P(APOE-ε4×P-tau217) = 0.00000826
Predicted Pr(cognitive impairment)
100% 75% 50% 25% 0%
-5 0 5
P-tau217 (log-z)
APOE ε4 status Non-carrier Carrier
C
Wisconsin
P(APOE-ε4×P-tau217) = 0.000317
-2.5 0.0 2.5 5.0
ADNI
P(APOE-ε4×P-tau217) = 0.00000619
-2 -1 0 1 2 3
EFIGA
P(APOE-ε4×P-tau217) = 0.0751
-5.0 -2.5 0.0 2.5
WHICAP
P(APOE-ε4×P-tau217) = 0.375
40% 30% 20% 10% 0%
-2.5 0.0 2.5
ROSMAP
P(APOE-ε4×P-tau217) = 0.221
-5 0 5
HABS-HD
P(APOE-ε4×P-tau217) = 0.18
-2.5 0.0 2.5 5.0

Figure 2. Cohort-specific and meta-analytic estimates of the association between *APOE*-ε4 carrier status and plasma P-tau217 levels in the full sample, among cognitively normal and P-tau217–negative individuals (A), and for *APOE*-ε4 associations with P-tau217 positivity (B)

Figure 2 presents cohort-specific and meta-analytic estimates of the association between *APOE*-ε4 carrier status and plasma P-tau217 levels in the full sample, among cognitively normal and P-tau217–negative individuals (A), as well as the associations between *APOE*-ε4 and P-tau217 positivity (B). Analyses were conducted at the time of first available biomarker measurement. For cohorts with only cross-sectional data, this corresponds to a single time point; for longitudinal cohorts, it reflects the earliest available biomarker. Plasma P-tau217 was harmonized using $\log_{10}$ transformation and z-standardization. All analyses used linear regression models adjusted for age, sex, education, and ethnicity; Random-effects meta-analyses were conducted using cohort-specific beta estimates. Cognitively normal was defined as the absence of a diagnosis of MCI or AD at the time of biomarker collection. P-tau217–negative status was defined as having P-tau217 levels below the cohort-specific threshold that maximized sensitivity or specificity.

A

Study	Beta (95% CI)	*P* (Beta)	N-Total
Analysis = All sample: APOE-ε4~P-tau217(log-z)			
Wisconsin	0.54 [0.44; 0.63]	0.00	1639
ADNI	0.73 [0.62; 0.84]	0.00	985
EFIGA	0.53 [0.43; 0.63]	0.00	1426
WHICAP	0.47 [0.33; 0.60]	0.00	1018
ROSMAP	0.44 [0.31; 0.56]	0.00	1035
HABS-HD	0.56 [0.49; 0.64]	0.00	2479
Random effects model	**0.55 [0.47; 0.62]**		
Heterogeneity: I^2 = 66.8%			
Analysis = Cognitive normal: APOE-ε4~P-tau217(log-z)			
Wisconsin	0.45 [0.36; 0.54]	0.00	1559
ADNI	0.37 [0.25; 0.49]	0.00	521
EFIGA	0.40 [0.27; 0.52]	0.00	820
WHICAP	0.44 [0.30; 0.58]	0.00	813
ROSMAP	0.35 [0.20; 0.50]	0.00	750
HABS-HD	0.49 [0.40; 0.57]	0.00	1852
Random effects model	**0.43 [0.39; 0.48]**		
Heterogeneity: I^2 = 0%			
Analysis = P-tau217 (-) (sen-cutoff): APOE-ε4~P-tau217(log-z)			
Wisconsin	0.17 [0.10; 0.24]	0.00	1177
ADNI	0.17 [0.09; 0.24]	0.00	484
EFIGA	0.14 [0.05; 0.23]	0.00	922
WHICAP	0.13 [0.01; 0.25]	0.03	628
ROSMAP	0.11 [-0.04; 0.25]	0.14	371
HABS-HD	0.16 [0.10; 0.22]	0.00	1698
Random effects model	**0.16 [0.12; 0.19]**		
Heterogeneity: I^2 = 0%			
Analysis = P-tau217 (-) (spec-cutoff): APOE-ε4~P-tau217(log-z)			
Wisconsin	0.27 [0.20; 0.35]	0.00	1452
ADNI	0.35 [0.27; 0.43]	0.00	669
EFIGA	0.29 [0.20; 0.38]	0.00	1255
WHICAP	0.29 [0.17; 0.40]	0.00	908
ROSMAP	0.15 [0.05; 0.26]	0.01	758
HABS-HD	0.33 [0.27; 0.40]	0.00	2230
Random effects model	**0.29 [0.24; 0.34]**		
Heterogeneity: I^2 = 50.9%			



B

Study	OR (95% CI)	*P* (OR)	N-Impaired	N-Normal
Analysis = APOE-ε4~Bio AD (sen-cutoff)				
Wisconsin	2.89 [2.28; 3.66]	0.00	462	1177
ADNI	5.64 [4.17; 7.63]	0.00	501	484
EFIGA	2.82 [2.22; 3.58]	0.00	504	922
WHICAP	2.30 [1.67; 3.16]	0.00	390	628
ROSMAP	2.05 [1.48; 2.86]	0.00	664	371
HABS-HD	3.15 [2.55; 3.89]	0.00	781	1698
Random effects model	**2.98 [2.33; 3.80]**			
Heterogeneity: I^2 = 80.1%				
Analysis = APOE-ε4~Bio AD (spec-cutoff)				
Wisconsin	5.08 [3.58; 7.22]	0.00	187	1452
ADNI	4.46 [3.31; 6.01]	0.00	316	669
EFIGA	3.67 [2.62; 5.14]	0.00	171	1255
WHICAP	2.59 [1.67; 4.00]	0.00	110	908
ROSMAP	2.96 [2.13; 4.10]	0.00	277	758
HABS-HD	4.53 [3.37; 6.09]	0.00	249	2230
Random effects model	**3.85 [3.16; 4.68]**			
Heterogeneity: I^2 = 51.1%				



Figure 3. Cohort-specific and meta-analytic hazard ratios for incident cognitive impairment in the full sample and *APOE*-stratified subgroups using harmonized continuous and binary P-tau217 measures, along with adjusted survival probabilities illustrating the temporal dynamics of P-tau217 in the pooled cohort.

Figure 3 presents cohort-specific hazard ratios for incident cognitive impairment in the full sample and *APOE*-stratified subgroups, using harmonized continuous and binary P-tau217 measures, along with meta-analytic estimates and adjusted survival probabilities illustrating the temporal dynamics of P-tau217 in the pooled cohort. Figure 3A shows results when P-tau217 is modeled as a continuous variable, Figure 3B shows results when P-tau217 positivity is defined using the sensitivity-based cut-off, and Figure 3C presents results when positivity is defined using the specificity-based cut-off. Given variability in longitudinal biomarker availability across cohorts, a standardized longitudinal analysis framework was applied. For each participant, baseline was defined as the time of first available biomarker measurement. In cohorts with only cross-sectional biomarker data, this represents a single time point; in longitudinal cohorts, it corresponds to the earliest biomarker collection. Clinical follow-up data were linked to each participant's biomarker baseline, and only visits occurring after this time point were included. Analyses were restricted to individuals who were cognitively unimpaired at baseline and had follow-up data.

Incident cognitive impairment was defined as conversion from cognitively unimpaired to either MCI or AD. Time-to-event was defined as the interval from baseline to the date of diagnosis for converters or to the last available follow-up for censored cases. Cox proportional hazards models were used, adjusting for age, sex, education, ethnicity, and *APOE* genotype. The proportional hazards assumption was tested using Schoenfeld residuals. Within each full or stratified subgroup, random-effects meta-analyses were conducted using cohort-specific estimates. P-tau217 positivity was defined using cohort-specific thresholds that maximized sensitivity or specificity. Continuous P-tau217 was harmonized using $\log_{10}$ transformation and z-standardization. P(Schoenfeld) indicates the p-value from the Schoenfeld global test for proportional hazards.

For the adjusted survival curve and to maximize statistical power, data from all cohorts were combined. P-tau217 positivity was defined within each cohort using thresholds that maximized sensitivity or specificity, then pooled across cohorts. Log-transformation and standardization of continuous P-tau217 levels were performed within each individual cohort and then combined without further standardization; thus, the values in the combined cohort reflect cohort-specific standardized units rather than a single unified global scale. Because the proportional hazards assumption was violated in the combined sample, we applied a pseudo-value approach (adjustedCurves package in R) when modelling P-tau217 as a binary positivity measure to address this issue. This method estimates survival probabilities at prespecified time points, adjusts for covariates (age,

sex, education, cohort, ethnicity, and *APOE* genotype), and averages predictions across groups. In cohorts with small or rare *APOE* genotypes (e.g., EFIGA), association models did not adjust for *APOE* genotype. Confidence intervals were obtained from 1,000 bootstrap resamples. For continuous P-tau217 measures, a pseudo-value model was not available, so we addressed violations of the proportional hazards assumption by stratifying on the covariates that failed the Schoenfeld global test before plotting the survival curves. We then plotted covariate-adjusted survival curves at pre-defined P-tau217 levels (e.g., the cohort-specific mean and +1 SD) to allow clinically meaningful comparisons, as +1 SD reflects a clearly elevated P-tau217 level relative to the cohort average.


A
Study P (Schoenfeld) Hazard Ratio (95% CI) P (HR) N-Event N-Censored
Sample = Full sample (Baseline P-tau217 level, log-z)
Wisconsin 0.34 2.16 [1.72; 2.71] 0.00 65 1073
ADNI 0.22 1.35 [1.16; 1.58] 0.00 146 255
EFIGA 0.59 1.35 [0.98; 1.86] 0.07 43 286
WHICAP 0.76 1.15 [1.03; 1.29] 0.01 342 458
ROSMAP 0.07 1.35 [1.19; 1.53] 0.00 340 392
HABS-HD 0.74 1.41 [1.21; 1.65] 0.00 172 997
Random effects model 1.41 [1.22; 1.64]
Heterogeneity: I² = 79.6%
Sample = ε3ε4/ε4ε4 (Baseline P-tau217 level, log-z)
Wisconsin 0.52 3.23 [2.19; 4.78] 0.00 33 378
ADNI 0.57 2.27 [1.61; 3.20] 0.00 57 89
EFIGA 0.19 1.17 [0.62; 2.21] 0.62 12 85
WHICAP 0.28 1.51 [1.17; 1.96] 0.00 87 108
ROSMAP 0.08 1.44 [1.17; 1.78] 0.00 90 89
HABS-HD 0.85 1.49 [1.07; 2.07] 0.02 47 232
Random effects model 1.76 [1.36; 2.26]
Heterogeneity: I² = 72.5%
Sample = ε2ε3/ε3ε3 (Baseline P-tau217 level, log-z)
Wisconsin 0.56 1.67 [1.19; 2.34] 0.00 32 695
ADNI 0.42 1.16 [0.95; 1.42] 0.14 89 166
EFIGA 0.89 1.44 [1.01; 2.06] 0.04 31 201
WHICAP 0.39 1.07 [0.93; 1.22] 0.35 255 350
ROSMAP 0.23 1.28 [1.10; 1.49] 0.00 250 303
HABS-HD 0.14 1.37 [1.15; 1.65] 0.00 125 765
Random effects model 1.26 [1.12; 1.42]
Heterogeneity: I² = 50.9%
0.3 0.5 1 2 10
Full sample
ε3ε4/ε4ε4
ε2ε3/ε3ε3
Survival Probability
Year 3
Year 4
N.S.
Time (years)
Baseline P-tau217 levels Mean 1 SD+
B
Study P (Schoenfeld) Hazard Ratio (95% CI) P (HR) N-Exposed N-Event N-Censored
Sample = Full sample (Baseline P-tau217 positivity, sen cutoff)
Wisconsin 0.77 3.99 [2.32; 6.86] 0.00 295 65 1073
ADNI 0.39 2.39 [1.68; 3.39] 0.00 139 146 255
EFIGA 0.36 1.98 [1.03; 3.80] 0.04 83 43 286
WHICAP 0.90 1.19 [0.94; 1.51] 0.14 269 342 458
ROSMAP 0.10 1.31 [1.04; 1.66] 0.02 415 340 392
HABS-HD 0.60 1.47 [1.05; 2.05] 0.02 340 172 997
Random effects model 1.77 [1.30; 2.43]
Heterogeneity: I² = 79.9%
Sample = ε3ε4/ε4ε4 (Baseline P-tau217 positivity, sen cutoff)
Wisconsin 0.55 8.89 [2.97; 26.63] 0.00 151 33 378
ADNI 0.75 5.77 [2.53; 13.14] 0.00 70 57 89
EFIGA 0.59 1.94 [0.50; 7.61] 0.34 35 12 85
WHICAP 0.06 1.64 [1.02; 2.62] 0.04 90 87 108
ROSMAP 0.13 1.64 [1.02; 2.65] 0.04 112 90 89
HABS-HD 0.93 1.18 [0.62; 2.23] 0.62 121 47 232
Random effects model 2.37 [1.38; 4.08]
Heterogeneity: I² = 71.3%
Sample = ε2ε3/ε3ε3 (Baseline P-tau217 positivity, sen cutoff)
Wisconsin 0.91 2.07 [0.95; 4.54] 0.07 144 32 695
ADNI 0.80 1.99 [1.29; 3.06] 0.00 69 89 166
EFIGA 0.55 1.80 [0.83; 3.90] 0.13 48 31 201
WHICAP 0.70 1.05 [0.79; 1.38] 0.76 179 255 350
ROSMAP 0.09 1.25 [0.95; 1.64] 0.11 303 250 303
HABS-HD 0.06 1.57 [1.07; 2.32] 0.02 219 125 765
Random effects model 1.43 [1.14; 1.79]
Heterogeneity: I² = 44.2%
0.3 0.5 1 2 10
Full sample
ε3ε4/ε4ε4
ε2ε3/ε3ε3
Survival Probability
Year 2
Year 2
N.S.
Time (years)
P-tau217 (sen-cutoff) Negative Positive
C
Study P (Schoenfeld) Hazard Ratio (95% CI) P (HR) N-Exposed N-Event N-Censored
Sample = Full sample (Baseline P-tau217 positivity, spec cutoff)
Wisconsin 0.18 5.64 [3.10; 10.26] 0.00 99 65 1073
ADNI 0.51 1.62 [1.06; 2.48] 0.03 50 146 255
EFIGA 0.76 5.92 [2.43; 14.40] 0.00 8 43 286
WHICAP 0.90 2.08 [1.47; 2.94] 0.00 66 342 458
ROSMAP 0.14 1.90 [1.47; 2.46] 0.00 135 340 392
HABS-HD 0.59 3.50 [2.27; 5.41] 0.00 84 172 997
Random effects model 2.74 [1.90; 3.96]
Heterogeneity: I² = 76.9%
Sample = ε3ε4/ε4ε4 (Baseline P-tau217 positivity, spec cutoff)
Wisconsin 0.24 6.24 [2.74; 14.20] 0.00 68 33 378
ADNI 0.70 2.25 [1.22; 4.16] 0.01 27 57 89
EFIGA 0.32 6.61 [1.20; 36.41] 0.03 3 12 85
WHICAP 0.13 2.23 [1.33; 3.76] 0.00 30 87 108
ROSMAP 0.09 2.50 [1.56; 4.02] 0.00 47 90 89
HABS-HD 0.82 3.65 [1.76; 7.57] 0.00 39 47 232
Random effects model 2.90 [2.12; 3.97]
Heterogeneity: I² = 23.8%
Sample = ε2ε3/ε3ε3 (Baseline P-tau217 positivity, spec cutoff)
Wisconsin 0.41 2.87 [0.83; 9.89] 0.10 31 32 695
ADNI 0.50 1.20 [0.64; 2.25] 0.57 23 89 166
EFIGA 0.08 6.86 [2.15; 21.85] 0.00 5 31 201
WHICAP 0.60 2.04 [1.28; 3.25] 0.00 36 255 350
ROSMAP 0.39 1.66 [1.20; 2.29] 0.00 88 250 303
HABS-HD 0.11 3.32 [1.91; 5.76] 0.00 45 125 765
Random effects model 2.19 [1.50; 3.20]
Heterogeneity: I² = 57.4%
0.3 0.5 1 2 10
Full sample
ε3ε4/ε4ε4
ε2ε3/ε3ε3
Survival Probability
Year 1
Year 1
Year 2
Time (years)
P-tau217 (spec-cutoff) Negative Positive

Figure 4. Baseline and longitudinal prognostic performance of plasma P-tau217 levels and positivity for cognitive impairment in the pooled cohort, as assessed by AUC, incremental R^2, and Harrell's C-index.

Figure 4 showed baseline and longitudinal prognostic performance of plasma P-tau217 levels and positivity for cognitive impairment in the pooled cohort. Figure 4A shows results when P-tau217 is modeled as a continuous variable, Figure 4B shows results when P-tau217 positivity is defined using the sensitivity-based cut-off, and Figure 4C presents results when positivity is defined using the specificity-based cut-off. Receiver operating characteristic (ROC) curves were obtained from logistic regression models adjusted for age, sex, education, cohort, and ethnic group. The *APOE*-ε4 model included *APOE*-ε4 status with covariates; the P-tau217 model included plasma P-tau217 with covariates; and the P-tau217 (ε4 carriers) and P-tau217 (non-carriers) models included plasma P-tau217 with covariates, fitted separately within *APOE*-ε4 carrier and non-carrier groups. Incremental Nagelkerke's R^2 was defined as the increase in model fit when adding the predictor of interest to the covariate-only model. Harrell's C-indices were obtained from Cox proportional hazards models adjusted for the same covariates. The *APOE*-ε4 model included *APOE*-ε4 status with covariates; the P-tau217 model included plasma P-tau217 with covariates; and the P-tau217 (ε4 carriers) and P-tau217 (non-carriers) models included plasma P-tau217 with covariates, fitted separately within *APOE*-ε4 carrier and non-carrier groups.


A
B
C
Baseline ROC, log-z
Baseline ROC, sen-cutoff
Baseline ROC, spec-cutoff
Sensitivity (TPR)
1 - Specificity (FPR)
APOE ε4 (AUC = 0.774)
P-tau217 (AUC = 0.795)
P-tau217 (non-carriers) (AUC = 0.771)
P-tau217 (ε4 carriers) (AUC = 0.835)
P-tau217 (AUC = 0.784)
P-tau217 (non-carriers) (AUC = 0.764)
P-tau217 (ε4 carriers) (AUC = 0.816)
P-tau217 (AUC = 0.797)
P-tau217 (non-carriers) (AUC = 0.775)
P-tau217 (ε4 carriers) (AUC = 0.833)
Baseline Incremental R², log-z
Baseline Incremental R², sen-cutoff
Baseline Incremental R², spec-cutoff
Δ R²
0.011
0.054
0.086
0.026
0.028
0.041
0.013
0.058
0.081
0.031
APOE ε4
P-tau217
P-tau217 (ε4 carriers)
P-tau217 (ε4 non-carriers)
C-index, log-z
C-index, sen-cutoff
C-index, spec-cutoff
C-index
0.686
0.709
0.777
0.683
0.698
0.755
0.677
0.706
0.758
0.684